Segulah Medical Acceleration
Stockholm, SwedenSegulah Medical Acceleration is a Stockholm-based growth and venture investor that takes minority stakes in Nordic and European medical device, diagnostics, life-science tools and digital-health companies with commercial-stage products, spun out of the Segulah private equity group.
Segulah Medical Acceleration is a Stockholm venture capital firm with €115M AUM, 8 active companies and 1 exit.
Sector breakdown
9 companiesGeography breakdown
3 geographiesKey facts
Recent exits
Segulah Medical Acceleration sold SAGA Dx to Foundation Medicine (Roche) in 2026 after 5 years.
Coverage notes
1 fund tracked, 9 portfolio companies (8 active · 1 realized). Verified weekly from public filings and deal announcements.
Funds & portfolio
Every fund Segulah Medical Acceleration has raised, with its portfolio companies. Hand-checked from public filings.
Segulah Medical AccelerationLife Sciences VC20218 assets1 exitsLife Sciences VC2021 · 5yr–81
Unrealized
8 held| Company | Entry |
|---|---|
| Basic Genomics Biotech · Sweden | 2025 |
| Collective Minds Radiology HealthTech · Sweden | 2023 |
| CytaCoat MedTech · Sweden | 2021 |
| Navinci Diagnostics Biotech · Sweden | 2022 |
| Protembis MedTech · Germany | 2024 |
| Quanta Dialysis Technologies MedTech · UK | 2021 |
| Senzime MedTech · Sweden | 2023 |
| Signifier Medical Technologies MedTech · UK | 2021 |
Realized
1 exit| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| SAGA Dx MedTech · Sweden | 2021 | 2026 | Trade Sale | Foundation Medicine (Roche) | – |
About Segulah Medical Acceleration
Segulah Medical Acceleration is the sole Nordic GP fully dedicated to medtech commercialisation with SEK 1.25-1.3 billion (~€110-125 million) of assets under management as of December 2024 (initial commitments c. SEK 1.2 billion), headquartered in Stockholm. The firm was founded in 2021 as an independent medtech specialist established with backing from leading Nordic institutions and prominent private investors. Segulah Medical operates independently from Segulah Advisor (Nordic buyout firm) despite shared Segulah heritage branding.
Investment thesis
Segulah Medical Acceleration deploys capital through one active fund (Segulah Medical Acceleration Fund I) plus co-investment sleeves, targeting medtech-only growth equity that provides early commercialisation capital (SEK 20-150 million ticket / ~€2-15 million) for medtech innovators transitioning from clinical validation to market scale. Sector focus spans medical devices, diagnostics, life science tools, digital health and healthcare technology and surgical and wound care. Geographic deployment is Europe with Nordic emphasis (Sweden, Denmark, Norway, Germany, UK) plus selective US. The medtech-only specialisation combines in-house operating expertise with an external network of medtech-industry veterans accelerating go-to-market.
Recent activity
Recent realised exits include healthcare technology (2024) and diagnostics (2026). Recent acquisitions include a wound care partnership (2024) and diagnostics CEO appointment and build (2024). The platform continues active deployment across the Nordic medtech commercialisation mandate.
Frequently asked questions
- What investment strategy does Segulah Medical Acceleration focus on?
- Segulah Medical Acceleration focuses on VC, Growth strategies in the private equity space.
- How many portfolio companies does Segulah Medical Acceleration have?
- Segulah Medical Acceleration has 8 active portfolio companies and 1 completed exit and 1 fund tracked on GP Intel.
- Where is Segulah Medical Acceleration headquartered?
- Segulah Medical Acceleration is headquartered in Stockholm, Sweden.
- What is Segulah Medical Acceleration's assets under management?
- Segulah Medical Acceleration manages approximately €115M in assets under management.
- When was Segulah Medical Acceleration founded?
- Segulah Medical Acceleration was founded in 2021.
- What sectors does Segulah Medical Acceleration invest in?
- Segulah Medical Acceleration invests across Healthcare.
- What are Segulah Medical Acceleration's recent exits?
- Recent realized exits by Segulah Medical Acceleration include: SAGA Dx (2026) to Foundation Medicine (Roche).
Similar firms
Other private equity firms tracked on GP Intel.
